Journal decision profile

Advanced Drug Delivery Reviews

Medicine · Biochemistry, Genetics and Molecular Biology

Advanced Drug Delivery Reviews' 2026 Journal Metrics Score is 14.3, ranking Q1 in Molecular Biology and 3 other subfields. Two-year citation average from OpenAlex data, updated August 2026.

Elsevier BVNetherlandspISSN 0169-409XeISSN 1872-8294
Checking system sharing availability.Visit homepage

Bookmark this page — track observed submission-to-acceptance timing, FWCI and field-normalized citation data for this journal in one view.

Journal Metrics Score
i
Journal Metrics ScoreThe raw score is citations received in the latest complete year by works from the two previous years, divided by the number of those works. It is calculated from OpenAlex open data (CC0) and is not a percentage grade.
2026
14.3

Journal Metrics Score 2026 · 2021–2024 window citedness 18.06.

Submission-to-acceptance
i
Submission-to-acceptanceCalendar days between the received and accepted dates reported in recent PubMed records. This interval includes editorial handling and author revisions, so it is not time to first decision or pure peer-review time.
PUBMED
114 daysmedian

Middle 50%: 82–163 days

100 of 100 PubMed-indexed articles · 100% coverage · 2024–2025

Indicative APC
i
Indicative APCThis journal-level estimate comes from the OpenAlex source record. It is not a verified quote and may exclude taxes, waivers, society discounts, or article-type charges. Check the journal's official website before deciding.
OPENALEX · VERIFY
$5,150

Journal-level estimate only. Verify current charges, taxes, waivers, discounts, and article-type fees with the journal.

Free preview · no sign-in

Does your manuscript fit Advanced Drug Delivery Reviews?

Paste your title to see which of this journal's published topics it overlaps with. Your title stays in your browser for this preview and is not sent anywhere.

Want ranked journals with fit reasons, risks and a submission strategy instead? See a sample AI report.

At a glance

Journal decision profile

Each spoke is a 0–100 percentile within a comparable journal cohort—not a percentage grade or a single black-box rating.

Relative profile

Metrics ScoreThe raw 2026 Journal Metrics Score is the recent two-year citation average shown above. The radar converts it to a 0–100 cohort percentile: farther out means a higher score than more comparable journals. It is not a percentage grade.iSource outputThe raw rank compares lifetime output inside the journal’s leading-topic source set. The radar then compares that rank position across Decision Profile journals in the same primary OpenAlex field; when that field has too few profiles, it uses the broader profile set. Farther out means relatively more output, not better research quality.iTop 10% shareThe share of recent papers in the global top 10% for citations after comparing papers of the same type, publication year, and subfield. The radar converts that share to a 0–100 cohort percentile; it does not predict how a new paper will perform.iMedian FWCICitation performance of the middle recent paper after field, year, and work type are considered. A raw FWCI of 1.0 is the expected citation level for comparable papers; the radar shows its 0–100 cohort percentile.iSubmission-to-acceptanceCalendar days from the received date to the accepted date in recent PubMed records. This includes editorial handling and author revisions, so it is not the time to first decision and not pure peer-review time. The radar uses a 0–100 cohort percentile with shorter observed timing plotted farther out; it does not measure review quality.iOutput volumeAverage works published per year in the recent analysis window, converted to a 0–100 cohort percentile. Farther out means the journal publishes more papers; it does not mean those papers are better.i
Cost is intentionally excluded. Missing APC data is never converted to a zero-dollar fee or a fabricated cost score.

Raw values behind the shape

Always visible
Metrics Score
i
Metrics ScoreThe 2026 raw Journal Metrics Score shown above. The bar is its 0–100 percentile within the radar's comparable journal cohort; it is not a percentage score.
14.32026 · OPENALEX
Source output rank
i
Source output rankThis lifetime journal-wide output rank compares works published by the OpenAlex source with sources associated with the journal’s leading topic. More output does not mean higher quality.
#129 / 1,424LIFETIME OUTPUT
Highly cited papers
i
Highly cited papersShare of recent works in the global top 10% for citations after comparing papers of the same type, publication year, and subfield.
66.1%FIELD-NORMALIZED TOP 10%
Field-normalized impact
i
Field-normalized impactCitation performance of the middle recent paper after field, year, and work type are considered. A raw FWCI of 1.0 is the expected level for comparable work.
4.09MEDIAN FWCI
Submission-to-acceptance
i
Submission-to-acceptanceReceived-to-accepted calendar days from qualified PubMed records. It includes editorial handling and author revisions; it is not time to first decision or pure peer-review time.
114 daysIQR 82–163 DAYS
Recent output
i
Recent outputAverage works published per year across the complete analysis window. This is a volume measure, not a quality score.
239 / yr2021–2024 AVG
Field-normalized top 10% share66.1%

633 of 957 works · same type, year & subfield

Field-normalized top 1% share15.3%

146 works · same type, year & subfield

Median FWCI4.09×

Above field-year expectation

Source output rank#129

of 1,424 topic-associated OpenAlex sources by lifetime output

What does Median FWCI mean?

FWCI compares papers with the same publication year, type, and field. 1.0 is the world average; above 1.0 is above expectation. This journal's median is 4.09, so its typical recent paper runs about 309% above its field benchmark.

What does Top 10% Share mean?

66.1% of recent papers rank in the global top 10% after field normalization. This is easier to compare across specialties than raw citation totals.

Publishing pattern

Publication volume and article mix

Volume is separated from citation accumulation so newer papers are not presented as weaker simply because they are newer.

Works published by year

OpenAlex source records · 2016–2025

1902016
1722017
1972018
1162019
1862020
3382021
2762022
2062023
1372024
1462025

Recent work-type mix

957 OpenAlex works · 2021–2024

Article92.6%
Paratext5.1%
Editorial1.5%
Erratum0.6%
Review0.2%
OpenAlex article is broader than “original research.” PubMed Publication Types can add case-report and clinical-study detail.
Fit signals

Topics and medical subject coverage

OpenAlex topics show research communities; MeSH keeps the medical taxonomy recognizable.

Major MeSH signals

PubMed-indexed works

Select a MeSH signal to see how much Advanced Drug Delivery Reviews publishes on it, from PubMed counts for the last five complete years.

Leading OpenAlex topics

2021–2024 works
RNA Interference and Gene Delivery75
Nanoparticle-Based Drug Delivery69
Extracellular vesicles in disease50
Diverse Scientific and Economic Studies49
3D Printing in Biomedical Research45
Nanoplatforms for cancer theranostics45
Advanced Drug Delivery Systems31
Inhalation and Respiratory Drug Delivery27
Immunotherapy and Immune Responses25
Advancements in Transdermal Drug Delivery23
Methodology: OpenAlex snapshot 2026-08-12. FWCI, percentile badges, topics, and type mix use 957 works published 2021–2024. Radar normalization is versioned in the cached profile, and no cost score is assigned without reliable APC data.

Subject Category Quartiles

Quartiles computed within each OpenAlex subfield
CategoryQuartile
Molecular BiologyQ1
BiomaterialsQ1
Pharmaceutical ScienceQ1
Biomedical EngineeringQ1

Is Advanced Drug Delivery Reviews a good journal?

Yes. One of the most-cited journals in Biology & Basic Science

Yes. By citation data, Advanced Drug Delivery Reviews is one of the most-cited journals in Biology & Basic Science: it ranks #53 of 3,784 Biology & Basic Science journals by Journal Metrics Score (top 2%) and is Q1 in Molecular Biology and 3 other subfields. Advanced Drug Delivery Reviews' 2026 Journal Metrics Score is 14.3. Recent papers took a median of 114 days from submission to acceptance, according to PubMed dates. OpenAlex lists an indicative article processing charge of $5,150 USD. OpenAlex classifies its papers in subfields including Molecular Biology, Biomaterials, and Pharmaceutical Science, so check that your topic fits its scope.

Best quartile
Q1
Molecular Biology
Rank in Biology & Basic Science
#53 of 3,784
Top 2%
2026 Journal Metrics Score
14.3
Acceptance rate
Not published
By the journal or publisher
Submission to acceptance
114 days
Median, PubMed records
Indicative APC
$5,150
OpenAlex, verify with the journal
Papers published in 2025
146
OpenAlex works

Check before you submit

  • Confirm the current article processing charge, waivers, and any institutional agreement on the journal website; the OpenAlex figure is indicative.
  • Confirm the journal is indexed where your institution or funder requires (for example Scopus or PubMed) before you submit.

Verdict from citation data only: quartile and field rank by Journal Metrics Score (OpenAlex), publisher-reported acceptance rates, and PubMed submission and acceptance dates. See how we rank journals and how to verify indexing.

Q1
Subfield Quartile
B1
CAS Block

Ranking and source check

#53
of 3,784 Biology & Basic Science field journals
#53
among Q1 Biology & Basic Science journals

Confirm the exact title and ISSNs against the publisher homepage before a high-stakes submission decision.

Journal Details

OpenAlex Works
5,438
H-Index
431
Fully Open Access
No
Recent OA Works
1,241
Subject Areas
BiomaterialsPharmaceutical ScienceMolecular Biology

Source: the current OpenAlex source record. OpenAlex works can include multiple work types. Fully Open Access is a source-level flag. Recent OA Works is summed from OpenAlex's counts_by_year series (up to the latest ten years); it is not a lifetime OA percentage. Any APC shown here is an indicative OpenAlex value—verify current charges on the journal's official website.

How to submit to Advanced Drug Delivery Reviews

  1. 1

    Check the scope

    OpenAlex classifies Advanced Drug Delivery Reviews' papers in subfields including Molecular Biology, Biomaterials, and Pharmaceutical Science. Read the aims and scope page and a few recent papers close to your topic before you prepare the manuscript.

  2. 2

    Follow the author guidelines

    Article types, word and figure limits, reference style, and the required statements (data availability, ethics, conflicts of interest, author contributions) are set by the journal. Prepare the cover letter and files to match them.

    Advanced Drug Delivery Reviews homepage ↗
  3. 3

    Submit through Editorial Manager

    Most Elsevier and Cell Press journals take submissions through Editorial Manager; each journal has its own site, reached from Submit your article on the journal homepage.

  4. 4

    Plan for costs

    OpenAlex lists an indicative article processing charge of $5,150 USD. Check the current fee, waivers, and any institutional agreement on the journal website.

  5. 5

    Know what to expect

    Recent accepted papers took a median of 114 days from submission to acceptance, including revisions (PubMed dates). Advanced Drug Delivery Reviews does not publish an acceptance rate.

Submission system from the publisher's author information, checked 2026-10-27. Individual journals can differ, so follow the link in the journal's own author guidelines.

New on PubMed

What's new in your field?

Type a topic to see the newest PubMed papers from the past week and the big picture of what they found, summarized by Claude on the Pro plan. Get a free weekly email to keep up.

See a demo:GLP-1CRISPRLong COVID

Reviewer Two · coming soon

Know what reviewers will say before you submit to Advanced Drug Delivery Reviews

An AI pre-submission report on your manuscript: the objections a tough reviewer is likely to raise, desk-rejection risks, and better-fit journals from our data. $29 per report.

See what the report covers

Common questions about Advanced Drug Delivery Reviews

Is Advanced Drug Delivery Reviews a good journal?

Yes. By citation data, Advanced Drug Delivery Reviews is one of the most-cited journals in Biology & Basic Science: it ranks #53 of 3,784 Biology & Basic Science journals by Journal Metrics Score (top 2%) and is Q1 in Molecular Biology and 3 other subfields. Advanced Drug Delivery Reviews' 2026 Journal Metrics Score is 14.3. Recent papers took a median of 114 days from submission to acceptance, according to PubMed dates. OpenAlex lists an indicative article processing charge of $5,150 USD. OpenAlex classifies its papers in subfields including Molecular Biology, Biomaterials, and Pharmaceutical Science, so check that your topic fits its scope.

What is Advanced Drug Delivery Reviews' Journal Metrics Score in 2026?

Advanced Drug Delivery Reviews' 2026 Journal Metrics Score is 14.3, from the August 2026 data release. The score is a two-year citation average computed from OpenAlex (CC0) data: citations received in the most recent complete year to works published in the two prior years, divided by the number of those works.

What is the acceptance rate of Advanced Drug Delivery Reviews?

We have not found an official acceptance rate published by Advanced Drug Delivery Reviews or its publisher, and Journal Metrics does not estimate one because submission counts are not public. What recent PubMed records do show is speed: accepted papers took a median of 114 days from submission to acceptance. To judge selectivity, compare Advanced Drug Delivery Reviews' quartile and score with similar journals, or ask the editorial office.

What quartile is Advanced Drug Delivery Reviews in?

Advanced Drug Delivery Reviews' best quartile is Q1. By OpenAlex subfield: Q1 in Molecular Biology; Q1 in Biomaterials; Q1 in Pharmaceutical Science; Q1 in Biomedical Engineering. Quartiles rank journals by Journal Metrics Score within each subfield.

Is the Journal Metrics Score the same as other journal citation metrics?

No. Journal Metrics computes the score independently from OpenAlex open data. Other providers use different citation databases, document types, and counting rules, so their published figures for Advanced Drug Delivery Reviews will not match this score exactly. Compare journals using one source at a time.

How long does Advanced Drug Delivery Reviews take from submission to acceptance?

Across 100 recent PubMed records with both dates, Advanced Drug Delivery Reviews took a median of 114 days from submission to acceptance; the middle half took 82–163 days. This interval includes editorial handling and revisions, so it is not the time to a first decision.

How much does it cost to publish in Advanced Drug Delivery Reviews?

OpenAlex lists an indicative article processing charge of $5,150 USD for Advanced Drug Delivery Reviews. This journal-level estimate may exclude taxes, waivers, discounts, or article-type fees, so confirm the current charge on the journal's website.

Which journals are alternatives to Advanced Drug Delivery Reviews?

Comparable journals include Journal of Controlled Release, Asian Journal of Pharmaceutical Sciences, Journal of Drug Targeting, and International Journal of Nanomedicine. Compare their scores, acceptance times, and costs in the recommended alternatives on this page before choosing where to submit.

How do I submit a paper to Advanced Drug Delivery Reviews?

Most Elsevier and Cell Press journals take submissions through Editorial Manager; each journal has its own site, reached from Submit your article on the journal homepage. Before submitting, check the scope, follow the author guidelines for article type, length, and required statements, and prepare a cover letter. Accepted papers took a median of 114 days from submission to acceptance in recent PubMed records.

Cite an article from this journal
Back to Search